Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

The new bill would ban mRNA vaccines for a decade. upi A freshman Idaho lawmaker wants to ban most COVID-19 shots for the ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain ...

Lougheed, said the findings of the report were “shocking” and that the information it presents to the public is “long overdue ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.